Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
20 studies found for:    Open Studies | "Breast Neoplasms, Male"
Show Display Options
Rank Status Study
1 Recruiting Tamoxifen +/- GnRH Analogue vs Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients
Condition: Male Breast Cancer
Interventions: Drug: Tamoxifen;   Drug: Tamoxifen and GnRH analogue;   Drug: Exemestane and GnRH analogue
2 Not yet recruiting Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)
Conditions: Breast Neoplasm;   Breast Neoplasm, Male
Interventions: Drug: Cyclophosphamide;   Drug: Indomethacin;   Drug: Omeprazole;   Dietary Supplement: Multivitamin
3 Recruiting Male Breast Cancer: Understanding the Biology for Improved Patient Care
Condition: Breast Cancer
Intervention:
4 Recruiting Sense of Hope Alleviates Fatigue in Breast Cancer Survivors
Condition: Carcinoma of Male Breast
Intervention:
5 Recruiting CLARITY(CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel) Trial (INO-VT-464-006; NCT02580448)
Conditions: Cancer of the Breast;   Breast Cancer;   Advanced Breast Cancer;   Metastatic Breast Cancer;   Male Breast Cancer;   Triple Negative Breast Cancer;   ER+ Breast Cancer
Interventions: Drug: Female AR(+) TNBC Enzalutamide Naïve;   Drug: Female AR(+) TNBC Enzalutamide Treated;   Drug: Female ER(+) BC Patients;   Drug: Male ER(+) BC Patients
6 Recruiting Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
Conditions: Estrogen Receptor Positive;   HER2/Neu Negative;   Male Breast Carcinoma;   Progesterone Receptor Positive;   Recurrent Breast Carcinoma;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: Entinostat;   Drug: Exemestane;   Drug: Goserelin Acetate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Other: Placebo;   Other: Quality-of-Life Assessment
7 Recruiting Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Male Breast Cancer;   Recurrent Breast Cancer;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: mifepristone;   Drug: carboplatin;   Drug: gemcitabine hydrochloride;   Other: laboratory biomarker analysis;   Other: pharmacological study
8 Recruiting Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery
Conditions: Male Breast Cancer;   Recurrent Melanoma;   Stage IV Breast Cancer;   Stage IV Melanoma;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Unspecified Adult Solid Tumor, Protocol Specific;   Hepatocellular Carcinoma
Interventions: Drug: propranolol hydrochloride;   Other: Correlative Studies
9 Recruiting Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer
Conditions: Male Breast Carcinoma;   Prostate Adenocarcinoma;   Recurrent Breast Carcinoma;   Recurrent Non-Small Cell Lung Carcinoma;   Recurrent Prostate Carcinoma;   Stage IV Breast Cancer;   Stage IV Non-Small Cell Lung Cancer;   Stage IV Prostate Cancer
Intervention: Radiation: Stereotactic Radiosurgery
10 Recruiting Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer
Conditions: Ductal Breast Carcinoma in Situ;   Lobular Breast Carcinoma in Situ;   Male Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Dietary Supplement: omega-3 fatty acid;   Other: placebo;   Other: laboratory biomarker analysis
11 Recruiting 18F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
Conditions: Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Male Breast Cancer;   Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma;   Recurrent Adenoid Cystic Carcinoma of the Oral Cavity;   Recurrent Adult Brain Tumor;   Recurrent Basal Cell Carcinoma of the Lip;   Recurrent Breast Cancer;   Recurrent Colon Cancer;   Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Hypopharyngeal Cancer;   Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Recurrent Laryngeal Cancer;   Recurrent Lip and Oral Cavity Cancer;   Recurrent Lymphoepithelioma of the Nasopharynx;   Recurrent Lymphoepithelioma of the Oropharynx;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Recurrent Mucoepidermoid Carcinoma of the Oral Cavity;   Recurrent Nasopharyngeal Cancer;   Recurrent Non-small Cell Lung Cancer;   Recurrent Oropharyngeal Cancer;   Recurrent Pancreatic Cancer;   Recurrent Paranasal Sinus and Nasal Cavity Cancer;   Recurrent Rectal Cancer;   Recurrent Renal Cell Cancer;   Recurrent Salivary Gland Cancer;   Stage IIIA Breast Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Stage IV Non-small Cell Lung Cancer;   Stage IV Pancreatic Cancer;   Stage IV Renal Cell Cancer;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVA Salivary Gland Cancer;   Stage IVB Colon Cancer;   Stage IVB Salivary Gland Cancer;   Stage IVC Salivary Gland Cancer;   Tongue Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Radiation: fludeoxyglucose F 18;   Radiation: 2-fluoropropionyl-labeled pegylated dimeric RGD peptide;   Procedure: positron emission tomography;   Procedure: computed tomography;   Other: laboratory biomarker analysis
12 Recruiting PHASE II TRIAL OF THE CYCLIN-DEPEDENT KINASE INHIBITOR PD 0332991 IN PATIENTS WITH CANCER
Conditions: Adult Solid Tumor;   Adenocarcinoma of the Colon;   Adenocarcinoma of the Rectum;   Adult Central Nervous System Germ Cell Tumor;   Adult Teratoma;   Benign Teratoma;   Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   Familial Testicular Germ Cell Tumor;   HER2-negative Breast Cancer;   HER2-positive Breast Cancer;   Male Breast Cancer;   Ovarian Immature Teratoma;   Ovarian Mature Teratoma;   Ovarian Monodermal and Highly Specialized Teratoma;   Progesterone Receptor-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Recurrent Breast Cancer;   Recurrent Colon Cancer;   Recurrent Extragonadal Germ Cell Tumor;   Recurrent Extragonadal Non-seminomatous Germ Cell Tumor;   Recurrent Extragonadal Seminoma;   Recurrent Malignant Testicular Germ Cell Tumor;   Recurrent Melanoma;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Rectal Cancer;   Stage III Extragonadal Non-seminomatous Germ Cell Tumor;   Stage III Extragonadal Seminoma;   Stage III Malignant Testicular Germ Cell Tumor;   Stage III Ovarian Germ Cell Tumor;   Stage IV Breast Cancer;   Stage IV Colon Cancer;   Stage IV Extragonadal Non-seminomatous Germ Cell Tumor;   Stage IV Extragonadal Seminoma;   Stage IV Melanoma;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Rectal Cancer;   Testicular Immature Teratoma;   Testicular Mature Teratoma
Interventions: Drug: PD-0332991;   Other: pharmacological study
13 Recruiting Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer
Condition: Breast Cancer
Interventions: Procedure: palliative surgery;   Procedure: therapeutic conventional surgery;   Radiation: palliative radiation therapy;   Radiation: radiation therapy
14 Recruiting Molecular Mechanisms of Clinical Resistance to Targeted Therapy Among Patients With Breast Cancer
Condition: Breast Cancer
Interventions: Other: Blood draw;   Other: immunoenzyme technique;   Procedure: biopsy;   Procedure: histopathologic examination
15 Recruiting Breast Cancer Registry for Participants With Breast Cancer or Characteristics of Hereditary Breast Cancer
Conditions: Breast Cancer;   Precancerous Condition
Interventions: Other: medical chart review;   Other: questionnaire administration;   Other: study of socioeconomic and demographic variables;   Procedure: Excess human biological tissue;   Procedure: quality-of-life assessment
16 Recruiting Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Condition: Breast Cancer
Interventions: Drug: Herceptin;   Drug: NeuVax vaccine;   Drug: GM-CSF
17 Recruiting Docetaxel With or Without a Phytochemical in Treating Patients With Breast Cancer
Condition: Breast Cancer
Interventions: Dietary Supplement: Curcumin;   Drug: Taxotere
18 Not yet recruiting QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer
Condition: Cancer
Intervention: Biological: ETBX-021
19 Not yet recruiting Natural Supplements and a Special Diet in Eliminating Cancer-impacting Hormones From Sources Outside the Body in Patients With Early-Stage or Remission Prostate Cancer, Breast Cancer, or Uterine Cancer
Conditions: Breast Cancer;   Prostate Cancer;   Sarcoma
Interventions: Other: laboratory biomarker analysis;   Procedure: therapeutic dietary intervention
20 Recruiting S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer
Condition: Breast Cancer
Interventions: Drug: anastrozole;   Drug: everolimus;   Drug: exemestane;   Drug: goserelin acetate;   Drug: letrozole;   Drug: leuprolide acetate;   Drug: tamoxifen citrate;   Other: placebo

Study has passed its completion date and status has not been verified in more than two years.